查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584636

全球肺动脉高血压（PAH）治疗市场：依药物类型、给药途径、通路、地区、趋势分析、竞争格局、预测，2019-2030年

Pulmonary Arterial Hypertension Treatment Market, By Drug Type; By Route of Administration; By Distribution Channel; By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 448 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2030 年，全球肺动脉高血压(PAH) 治疗市场规模将达到 103 亿美元

由于肺动脉高压盛行率的上升、药物开发的进步、对该疾病的认识不断提高、医疗保健基础设施的改善以及对有效治疗方法的需求不断增长，全球肺动脉高血压（PAH）治疗市场预计将不断增长。 。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2023 年肺动脉高血压(PAH) 治疗的全球市场规模将达到 75 亿美元。 BlueWeave 预测，2024-2030 年期间，全球肺动脉高血压（PAH）治疗市场规模将以 4.80% 的复合年增长率成长，到 2030 年达到 102.8 亿美元。全球肺动脉高血压(PAH) 治疗市场是由 PAH 盛行率上升、对该疾病认识的提高以及标靶治疗的进步所推动的。医疗费用的增加、老年人口的增加以及药物联合治疗市场的开拓将进一步支持市场成长。此外，内皮素受体拮抗剂 (ERA)、磷酸二酯酶 5 抑制剂 (PDE-5i) 和前列腺环素类似物等新型药物的出现极大地扩展了治疗选择并改善了患者预后，这导致了疾病的改善，并成为市场的驱动力。

机会 -联合治疗的开发和采用

越来越多地采用联合治疗是全球肺动脉高血压（PAH）治疗市场的主要驱动因素。结合不同的药物类别，包括内皮素受体拮抗剂 (ERAs)、磷酸二酯酶 5 抑制剂 (PDE5Is) 和前列腺环素素类似物，可以透过针对多种疾病途径来改善患者的治疗效果。医疗保健提供者越来越多地采用这些疗法，因为它们可以提高治疗效果、减缓疾病进展并降低死亡率，从而推动市场成长。

地缘政治紧张局势加剧对全球肺动脉高血压（PAH）治疗市场的影响

地缘政治紧张局势加剧可能会影响供应链，导致药物短缺，并因受影响地区的不稳定性而推迟临床试验，从而扰乱全球肺动脉高血压（PAH）治疗市场。关税、制裁和贸易限制的增加可能会增加药品的生产和分销成本，并限制其在某些市场的供应。此外，经济不稳定和政府优先事项的变化可能会导致医疗保健资金流失，特别是在脆弱和新兴经济体，可能会影响多环芳烃研究投资、治疗成本和整体患者照护。

北美引领全球多环芳烃治疗市场

北美主导全球肺动脉高血压（PAH）治疗市场。北美的主导地位归因于该地区先进的医疗基础设施、对 PAH 的高度认识以及易于获得的治疗选择。此外，PAH 在美国的盛行率很高。对新治疗方法研发计划的大力投资支持了该地区的市场领导地位。该地区（尤其是美国）拥有世界领先的製药公司，使该地区在欧洲、亚太地区、拉丁美洲和中东地区的全球肺动脉高血压治疗（PAH）市场中处于关键地位。

竞争格局

全球肺动脉高血压（PAH）治疗市场竞争激烈，许多公司争夺更大的市场占有率。市场主要企业包括United Therapeutics Ltd、拜耳AG、Actelion Ltd、辉瑞公司、吉利德科学公司、葛兰素史克公司、梯瓦製药公司、礼来公司、Steady Med Ltd、Viatris Inc、Sandoz Inc、Lupin Pharmaceuticals 、 Inc.、太阳製药工业公司和强生公司。这些公司正在增加对研发活动、併购、合资、联盟、授权合约、新产品和服务的投资，以进一步巩固其在全球肺动脉高血压（PAH）治疗市场的地位。

该报告的详细分析提供了有关全球肺动脉高血压（PAH）治疗市场的成长潜力、未来趋势和统计数据的资讯。它还重点关注推动市场总规模预测的因素。该报告致力于提供全球肺动脉高血压（PAH）治疗市场的最新技术趋势以及产业见解，以帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章全球肺动脉高血压（PAH）治疗市场洞察

  • 分销通路价值链分析
  • DROC分析
    • 生长促进因子
      • 肺动脉高压盛行率增加
      • 治疗进展
      • 医疗费用增加
    • 抑制因素
      • 治疗费用高
      • 部分地区认识不足
      • 获得专业医疗护理的机会有限
    • 机会
      • 个人化医疗的进展
      • 联合治疗的发展
      • 对数位健康解决方案的需求增加
    • 任务
      • 开发和核准新的多环芳烃治疗方法的监管障碍
      • 获得 PAH 治疗报销
  • 科技进步/最新趋势
  • 法律规范
  • 波特五力分析

第四章全球肺动脉高血压（PAH）治疗市场：行销策略

第五章全球肺动脉高血压（PAH）治疗市场：价格分析

第六章全球肺动脉高血压（PAH）治疗市场：区域分析

  • 全球肺动脉高血压(PAH) 治疗市场，区域分析，2023 年
  • 2024-2030年全球肺动脉高血压（PAH）治疗市场吸引力分析

第七章全球肺动脉高血压（PAH）治疗市场概述

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依药物类型
      • 内皮素受体拮抗剂（ERA）
      • 磷酸二酯酶 5 (PDE-5) 抑制剂
      • 前列腺环素类似物
      • 可溶性鸟苷酸环化酶刺激剂
      • 其他的
    • 依给药途径
      • 口服
      • 静脉
      • 皮下的
      • 吸入
    • 按分销管道
      • 医院药房
      • 零售药房
      • 网路药房
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第八章北美肺动脉高血压（PAH）治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依药物类型
    • 依给药途径
    • 按分销管道
    • 按国家/地区
      • 美国
      • 加拿大

第九章欧洲肺动脉高血压（PAH）治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依药物类型
    • 依给药途径
    • 按分销管道
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第十章亚太肺动脉高血压（PAH）治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依药物类型
    • 依给药途径
    • 按分销管道
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他地区

第十一章拉丁美洲肺动脉高血压（PAH）治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依药物类型
    • 依给药途径
    • 按分销管道
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第十二章中东与非洲肺动脉高血压（PAH）治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依药物类型
    • 依给药途径
    • 按分销管道
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第十三章竞争格局

  • 主要参与者及其产品列表
  • 2023年全球肺动脉高血压（PAH）治疗公司市场占有率分析
  • 透过管理参数进行竞争基准基准化分析
  • 重大策略发展（合併、收购、联盟等）

第14章地缘政治紧张局势加剧对全球肺动脉高血压（PAH）治疗市场的影响

第十五章 公司简介（公司简介、财务矩阵、竞争格局、关键人员、主要竞争对手、联络方式、策略展望、SWOT分析）

  • United Therapeutics Ltd
  • Bayer AG
  • Actelion Ltd
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Steady Med Ltd
  • Viatris Inc.
  • Sandoz Inc.
  • Lupin Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries, Inc.
  • Johnson &Johnson
  • 其他主要企业

第十六章 主要策略建议

第十七章调查方法

简介目录
Product Code: BWC24793

Global Pulmonary Arterial Hypertension (PAH) Treatment Market Size to Touch USD 10.3 Billion by 2030

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease, improving healthcare infrastructure, and growing demand for effective therapies.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Pulmonary Arterial Hypertension (PAH) Treatment Market size by value at USD 7.50 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Pulmonary Arterial Hypertension (PAH) Treatment Market size to expand at a CAGR of 4.80% reaching a value of USD 10.28 billion by 2030. Global Pulmonary Arterial Hypertension (PAH) Treatment Market is driven by rising prevalence of PAH, growing awareness about the condition, and advancements in targeted therapies. Increasing healthcare expenditure, a growing geriatric population, and the development of combination drug therapies further fuel market growth. Additionally, the availability of novel drugs such as endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5i), and prostacyclin analogs significantly enhances treatment options, leading to improved patient outcomes and driving market expansion.

Opportunity - Development and Adoption of Combination Therapies

Increasing adoption of combination therapies is a key driver in Global Pulmonary Arterial Hypertension (PAH) Treatment Market. Combining different drug classes, such as endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE5Is), and prostacyclin analogs, has shown improved patient outcomes by targeting multiple disease pathways. These therapies enhance treatment efficacy, slow disease progression, and reduce mortality rates, which encourages healthcare providers to adopt them, thereby boosting market growth.

Impact of Escalating Geopolitical Tensions on Global Pulmonary Arterial Hypertension (PAH) Treatment Market

Escalating geopolitical tensions could disrupt Global Pulmonary Arterial Hypertension (PAH) Treatment Market by impacting supply chains, causing drug shortages, and delaying clinical trials due to instability in affected regions. Increased tariffs, sanctions, and trade restrictions may raise production and distribution costs for medications, limiting accessibility in certain markets. Additionally, economic instability and shifting government priorities may divert healthcare funding, affecting investment in PAH research, treatment affordability, and overall patient care, particularly in vulnerable or developing economies.

North America Leads Global PAH Treatment Market

North America dominates Global Pulmonary Arterial Hypertension (PAH) Treatment Market. Leadership position of North America is due to the region's advanced healthcare infrastructure, higher awareness about PAH, and greater accessibility to treatment options. Additionally, a higher prevalence of PAH in United States. Strong investments in R&D programs for new therapies support the region's market leadership. The strong presence of major global pharmaceutical companies in the region, particularly in United States, further contributes to the region's significant position in Global Pulmonary Arterial Hypertension Treatment (PAH) Market among Europe, Asia Pacific, Latin America, and Middle East and Africa.

Competitive Landscape

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include United Therapeutics Ltd, Bayer AG, Actelion Ltd, Pfizer, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Teva Pharmaceuticals Inc., Eli Lilly and Company, Steady Med Ltd, Viatris Inc., Sandoz Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Johnson & Johnson. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Pulmonary Arterial Hypertension (PAH) Treatment Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Pulmonary Arterial Hypertension (PAH) Treatment Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technological trends in Global Pulmonary Arterial Hypertension (PAH) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the Market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Pulmonary Arterial Hypertension Treatment Market Insights

  • 3.1. Distribution Channel Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of pulmonary arterial hypertension
      • 3.2.1.2. Advancements in treatment
      • 3.2.1.3. Rising healthcare spending
    • 3.2.2. Restraints
      • 3.2.2.1. High cost of treatments
      • 3.2.2.2. Lack of awareness in some regions
      • 3.2.2.3. Limited access to specialized care
    • 3.2.3. Opportunities
      • 3.2.3.1. Advances in personalized medicine
      • 3.2.3.2. Development of combination therapies
      • 3.2.3.3. Increasing demand for digital health solutions
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory hurdles for the development and approval of new PAH treatments
      • 3.2.4.2. Obtaining reimbursement for PAH treatments
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Pulmonary Arterial Hypertension Treatment Market: Marketing Strategies

5. Global Pulmonary Arterial Hypertension Treatment Market: Pricing Analysis

6. Global Pulmonary Arterial Hypertension Treatment Market: Geography Analysis

  • 6.1. Global Pulmonary Arterial Hypertension Treatment Market, Geographical Analysis, 2023
  • 6.2. Global Pulmonary Arterial Hypertension Treatment, Market Attractiveness Analysis, 2024-2030

7. Global Pulmonary Arterial Hypertension Treatment Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
      • 7.2.1.1. Endothelin Receptor Antagonists (ERAs)
      • 7.2.1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
      • 7.2.1.3. Prostacyclin Analogues
      • 7.2.1.4. Soluble Guanylate Cyclase Stimulators
      • 7.2.1.5. Others
    • 7.2.2. By Route of Administration
      • 7.2.2.1. Oral
      • 7.2.2.2. Intravenous
      • 7.2.2.3. Subcutaneous
      • 7.2.2.4. Inhalation
    • 7.2.3. By Distribution Channel
      • 7.2.3.1. Hospital Pharmacies
      • 7.2.3.2. Retail Pharmacies
      • 7.2.3.3. Online Pharmacies
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America Pulmonary Arterial Hypertension Treatment Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Drug Type
      • 8.2.4.1.2. By Route of Administration
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Drug Type
      • 8.2.4.2.2. By Route of Administration
      • 8.2.4.2.3. By Distribution Channel

9. Europe Pulmonary Arterial Hypertension Treatment Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Drug Type
      • 9.2.4.1.2. By Route of Administration
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Drug Type
      • 9.2.4.2.2. By Route of Administration
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Drug Type
      • 9.2.4.3.2. By Route of Administration
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. France
      • 9.2.4.4.1. By Drug Type
      • 9.2.4.4.2. By Route of Administration
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Drug Type
      • 9.2.4.5.2. By Route of Administration
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Drug Type
      • 9.2.4.6.2. By Route of Administration
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Drug Type
      • 9.2.4.7.2. By Route of Administration
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Drug Type
      • 9.2.4.8.2. By Route of Administration
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Drug Type
      • 9.2.4.9.2. By Route of Administration
      • 9.2.4.9.3. By Distribution Channel

10. Asia Pacific Pulmonary Arterial Hypertension Treatment Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Drug Type
      • 10.2.4.1.2. By Route of Administration
      • 10.2.4.1.3. By Distribution Channel
      • 10.2.4.2. India
      • 10.2.4.2.1. By Drug Type
      • 10.2.4.2.2. By Route of Administration
      • 10.2.4.2.3. By Distribution Channel
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Drug Type
      • 10.2.4.3.2. By Route of Administration
      • 10.2.4.3.3. By Distribution Channel
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Drug Type
      • 10.2.4.4.2. By Route of Administration
      • 10.2.4.4.3. By Distribution Channel
      • 10.2.4.5. Australia & New Zealand
      • 10.2.4.5.1. By Drug Type
      • 10.2.4.5.2. By Route of Administration
      • 10.2.4.5.3. By Distribution Channel
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Drug Type
      • 10.2.4.6.2. By Route of Administration
      • 10.2.4.6.3. By Distribution Channel
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Drug Type
      • 10.2.4.7.2. By Route of Administration
      • 10.2.4.7.3. By Distribution Channel
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Drug Type
      • 10.2.4.8.2. By Route of Administration
      • 10.2.4.8.3. By Distribution Channel
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Drug Type
      • 10.2.4.9.2. By Route of Administration
      • 10.2.4.9.3. By Distribution Channel
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Drug Type
      • 10.2.4.10.2. By Route of Administration
      • 10.2.4.10.3. By Distribution Channel

11. Latin America Pulmonary Arterial Hypertension Treatment Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Drug Type
      • 11.2.4.1.2. By Route of Administration
      • 11.2.4.1.3. By Distribution Channel
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Drug Type
      • 11.2.4.2.2. By Route of Administration
      • 11.2.4.2.3. By Distribution Channel
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Drug Type
      • 11.2.4.3.2. By Route of Administration
      • 11.2.4.3.3. By Distribution Channel
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Drug Type
      • 11.2.4.4.2. By Route of Administration
      • 11.2.4.4.3. By Distribution Channel
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Drug Type
      • 11.2.4.5.2. By Route of Administration
      • 11.2.4.5.3. By Distribution Channel

12. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Type
    • 12.2.2. By Route of Administration
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Drug Type
      • 12.2.4.1.2. By Route of Administration
      • 12.2.4.1.3. By Distribution Channel
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Drug Type
      • 12.2.4.2.2. By Route of Administration
      • 12.2.4.2.3. By Distribution Channel
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Drug Type
      • 12.2.4.3.2. By Route of Administration
      • 12.2.4.3.3. By Distribution Channel
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Drug Type
      • 12.2.4.4.2. By Route of Administration
      • 12.2.4.4.3. By Distribution Channel
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Drug Type
      • 12.2.4.5.2. By Route of Administration
      • 12.2.4.5.3. By Distribution Channel
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Drug Type
      • 12.2.4.6.2. By Route of Administration
      • 12.2.4.6.3. By Distribution Channel
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Drug Type
      • 12.2.4.7.2. By Route of Administration
      • 12.2.4.7.3. By Distribution Channel
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Drug Type
      • 12.2.4.8.2. By Route of Administration
      • 12.2.4.8.3. By Distribution Channel

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Pulmonary Arterial Hypertension Treatment Company Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Pulmonary Arterial Hypertension Treatment Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. United Therapeutics Ltd
  • 15.2. Bayer AG
  • 15.3. Actelion Ltd
  • 15.4. Pfizer, Inc.
  • 15.5. Gilead Sciences, Inc.
  • 15.6. GlaxoSmithKline plc
  • 15.7. Teva Pharmaceuticals Inc.
  • 15.8. Eli Lilly and Company
  • 15.9. Steady Med Ltd
  • 15.10. Viatris Inc.
  • 15.11. Sandoz Inc.
  • 15.12. Lupin Pharmaceuticals, Inc.
  • 15.13. Sun Pharmaceutical Industries, Inc.
  • 15.14. Johnson & Johnson
  • 15.15. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable